Neurological Nuance: Hodgkin lymphoma presenting with Guillain –BarrÉ syndrome

ConclusionsGBS preceding HL is rare, and this case highlights the importance of considering HL in the setting of GBS. Marked elevations in CSF protein, ongoing deterioration despite administration of IVIg, and constitutional symptoms with elevated inflammatory markers may be clues to possible HL‐induced GBS. Muscle Nerve, 2016
Source: Muscle and Nerve - Category: Internal Medicine Authors: Tags: Case of the Month Source Type: research

Related Links:

In this study, we evaluated ATA as a potential antiviral drug against ZIKV replication. The antiviral activity of ATA against ZIKV replication in vitro showed median inhibitory concentrations (IC50) of 13.87 ± 1.09 μM and 33.33 ± 1.13 μM in Vero and A549 cells, respectively; without showing any cytotoxic effect in both cell lines (median cytotoxic concentration (CC50)> 1,000 μM). Moreover, ATA protected both cell types from ZIKV-induced cytopathic effect (CPE) and apoptosis in a time- and concentration-dependent manner. In addition, pre-treatment of Vero cells with ATA for up to 72 h also resulted...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Conclusions: In pts with R/R cHL, therapy with Cami-T provided impressive ORRs and CR rates in a heavily pretreated pt population. A 45 µg/kg dose of Cami-T was identified as having optimal activity with an acceptable safety profile. Enrollment of pts with HL is now complete and initial response data for all pts with HL will be available later this year. This data supports further investigation in a planned Phase 2 study.Study sponsored by ADC Therapeutics. http://clinicaltrials.gov/show/NCT02432235.DisclosuresHamadani: Celgene Corporation: Consultancy; Cellerant: Consultancy; Janssen: Consultancy; ADC Therapeutics: ...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches Source Type: research
We describe a case of Guillain –Barré syndrome (GBS) in a patient treated with bevacizumab. Our case is a 60-year-old woman with Stewart–Treves syndrome (STS), and angiosarcoma of her left forearm, with onset 12 years after diagnosis with stage IIIA left breast cancer. She suffered from repeated distal metastases including skin, bone, and liver metastases. She underwent numerous treatments including left arm amputation, radiation, and chemotherapy, but her disease was resistant. Thereafter, she received bevacizumab. Two weeks following the first administration, she presented in poor physical conditi...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
Conclusions:Diagnostic approach to bilateral FNP should evaluate for: traumatic (skull fractures), infectious (classically Lyme disease), metabolic (diabetes), autoimmune (sarcoidosis, Guillain-Barré syndrome), congenital (Moebius syndrome) and neoplastic (brainstem tumors) entities. WM is a rare cause, a condition due to low-grade B cell lymphoma where lymphoplasmacytoid cells infiltrate different tissues and secrete monoclonal IgM. Peripheral neuropathy develops in 15–30% of the cases, usually a chronic, progressive, symmetric, predominantly distal polyneuropathy. Facial nerve impairment is unusual, caused b...
Source: Neurology - Category: Neurology Authors: Tags: Neuro-oncology: Brain and CNS Metastases Source Type: research
Conclusion:CNS manifestations are relatively common in patients with HME but GBS has not been previously reported. Our case illustrates the importance of a high index of clinical suspicion which will facilitate early diagnosis and initiate timely therapy, thus avoiding potentially life-threatening complications.Background:Not applicableDesign/Methods:Not applicableResults:Not applicableConclusions:Not applicableDisclosure: Dr. Zhu, MD has nothing to disclose. Dr. Arukala, MD has nothing to disclose. Dr. Sheikh, MD has nothing to disclose. Dr. Uprety, MD has nothing to disclose. Dr. McCrary, MD has nothing to disclose. Dr. ...
Source: Neurology - Category: Neurology Authors: Tags: Fungal and Parasitic Disease of the Nervous System Source Type: research
Hepatitis E virus (HEV) infections are not limited to the liver but may also affect other organs. Several diseases, including Guillain-Barr é syndrome, neuralgic amyotrophy, glomerulonephritis, cryoglobulinemia, pancreatitis, lymphoma, thrombopenia, meningitis, thyroiditis and myocarditis have been observed in the context of hepatitis E. To date, the definite pathophysiological links between HEV and extrahepatic manifestations are not yet established. However, it is suggested that HEV infection might be causative based on serological studies, case series, in vitro data and animal models.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Review Source Type: research
Hepatitis E virus (HEV) infections are not limited to the liver but may also affect other organs. Several diseases, including Guillain-Barr é syndrome, neuralgic amyotrophy, glomerulonephritis, cryoglobulinemia, pancreatitis, lymphoma, thrombopenia, meningitis, thyreoiditis and myocarditis have been observed in the context of hepatitis E. To date the definite pathophysiological links between HEV and extrahepatic manifestations are not yet established. However, it is suggested that HEV-infection might be causative based on serological studies, case series, in vitro data and animal models.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Review Source Type: research
Nelarabine is a purine analogue used for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma mainly as a bridge to stem cell transplantation. The water-soluble prodrug of 9-beta-D-arabinofuranosyl guanine (Ara-G) is phosphorylated within leukemic cells to form ara-G triphosphate (ara-GTP), which terminates DNA chain elongation, resulting in cell death. The drug received accelerated approval by the US Food and Drug Administration (FDA) on October 2005 based on the induction of complete remissions in 2 phase II trials.
Source: Current Problems in Cancer - Category: Cancer & Oncology Authors: Source Type: research
Nelarabine is a purine analogue used for the treatment of patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) mainly as a bridge to stem cell transplantation (SCT). The water-soluble prodrug of 9-beta-D-arabinofuranosyl guanine (Ara-G) is phosphorylated within leukemic cells to form ara-G triphosphate (ara-GTP), which terminates DNA chain elongation, resulting in cell death. The drug received accelarated approval by the U.S. Food and Drug Administration (FDA) on October 2005 based on the induction of complete remissions (CR) in two phase II trials.
Source: Current Problems in Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusions: Bilateral facial palsy is a rare medical condition, and treatment often requires a multidisciplinary approach. The authors outline diagnostic and therapeutic algorithms of a tertiary care center to provide clinicians with a systematic approach to managing these complicated patients.
Source: Plastic and Reconstructive Surgery - Category: Cosmetic Surgery Tags: Reconstructive: Head and Neck: Original Articles Source Type: research
More News: Cancer & Oncology | Chemotherapy | Guillain-Barr Syndrome | Internal Medicine | Lymphoma | Neurology | Study